BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21042729)

  • 1. Expression of P-glycoprotein in HeLa cells confers resistance to ceramide cytotoxicity.
    Chapman JV; Gouazé-Andersson V; Cabot MC
    Int J Oncol; 2010 Dec; 37(6):1591-7. PubMed ID: 21042729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells.
    Chapman JV; Gouazé-Andersson V; Karimi R; Messner MC; Cabot MC
    Exp Cell Res; 2011 Jul; 317(12):1736-45. PubMed ID: 21396934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells.
    Gouazé-Andersson V; Yu JY; Kreitenberg AJ; Bielawska A; Giuliano AE; Cabot MC
    Biochim Biophys Acta; 2007 Dec; 1771(12):1407-17. PubMed ID: 18035065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer.
    Morad SAF; Davis TS; MacDougall MR; Tan SF; Feith DJ; Desai DH; Amin SG; Kester M; Loughran TP; Cabot MC
    Biochem Pharmacol; 2017 Apr; 130():21-33. PubMed ID: 28189725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53.
    Morad SA; Madigan JP; Levin JC; Abdelmageed N; Karimi R; Rosenberg DW; Kester M; Shanmugavelandy SS; Cabot MC
    Biochem Pharmacol; 2013 Apr; 85(8):1057-65. PubMed ID: 23353700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to the antiproliferative effect induced by a short-chain ceramide is associated with an increase of glucosylceramide synthase, P-glycoprotein, and multidrug-resistance gene-1 in cervical cancer cells.
    Gutiérrez-Iglesias G; Hurtado Y; Palma-Lara I; López-Marure R
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):809-17. PubMed ID: 25113261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism of short-chain ceramide by human cancer cells--implications for therapeutic approaches.
    Chapman JV; Gouazé-Andersson V; Messner MC; Flowers M; Karimi R; Kester M; Barth BM; Liu X; Liu YY; Giuliano AE; Cabot MC
    Biochem Pharmacol; 2010 Aug; 80(3):308-15. PubMed ID: 20385104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells.
    Lavie Y; Cao Ht; Volner A; Lucci A; Han TY; Geffen V; Giuliano AE; Cabot MC
    J Biol Chem; 1997 Jan; 272(3):1682-7. PubMed ID: 8999846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells.
    Lucci A; Han TY; Liu YY; Giuliano AE; Cabot MC
    Cancer; 1999 Jul; 86(2):300-11. PubMed ID: 10421266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SDZ PSC 833 the drug resistance modulator activates cellular ceramide formation by a pathway independent of P-glycoprotein.
    Goulding CW; Giuliano AE; Cabot MC
    Cancer Lett; 2000 Feb; 149(1-2):143-51. PubMed ID: 10737718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy.
    Gouazé V; Yu JY; Bleicher RJ; Han TY; Liu YY; Wang H; Gottesman MM; Bitterman A; Giuliano AE; Cabot MC
    Mol Cancer Ther; 2004 May; 3(5):633-9. PubMed ID: 15141021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-estrogen receptor drug, tamoxifen, is selectively Lethal to P-glycoprotein-expressing Multidrug resistant tumor cells.
    Bakadlag R; Limniatis G; Georges G; Georges E
    BMC Cancer; 2023 Jan; 23(1):24. PubMed ID: 36609245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells.
    Tyler A; Johansson A; Karlsson T; Gudey SK; Brännström T; Grankvist K; Behnam-Motlagh P
    Exp Cell Res; 2015 Aug; 336(1):23-32. PubMed ID: 26004871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance.
    Liu YY; Han TY; Giuliano AE; Hansen N; Cabot MC
    J Biol Chem; 2000 Mar; 275(10):7138-43. PubMed ID: 10702281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P-glycoprotein is implicated in the inhibition of ceramide-induced apoptosis in TF-1 acute myeloid leukemia cells by modulation of the glucosylceramide synthase pathway.
    Turzanski J; Grundy M; Shang S; Russell N; Pallis M
    Exp Hematol; 2005 Jan; 33(1):62-72. PubMed ID: 15661399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucosylceramide synthase inhibition enhances vincristine-induced cytotoxicity.
    Olshefski RS; Ladisch S
    Int J Cancer; 2001 Jul; 93(1):131-8. PubMed ID: 11391632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CIP2A is associated with multidrug resistance in cervical adenocarcinoma by a P-glycoprotein pathway.
    Liu J; Wang M; Zhang X; Wang Q; Qi M; Hu J; Zhou Z; Zhang C; Zhang W; Zhao W; Wang X
    Tumour Biol; 2016 Feb; 37(2):2673-82. PubMed ID: 26404133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs.
    Shabbits JA; Mayer LD
    Mol Cancer Ther; 2002 Jan; 1(3):205-13. PubMed ID: 12467215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceramide glycosylation potentiates cellular multidrug resistance.
    Liu YY; Han TY; Giuliano AE; Cabot MC
    FASEB J; 2001 Mar; 15(3):719-30. PubMed ID: 11259390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lactoferricin-induced apoptosis in estrogen-nonresponsive MDA-MB-435 breast cancer cells is enhanced by C6 ceramide or tamoxifen.
    Furlong SJ; Mader JS; Hoskin DW
    Oncol Rep; 2006 May; 15(5):1385-90. PubMed ID: 16596215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.